From Yahoo Finance: 2025-04-08 06:13:00

President Trump’s trade policies are impacting stocks, creating opportunities for investors to find bargains. However, companies like Tilray and Novavax, trading below $10, face challenges. Tilray struggles with poor financial results and regulatory issues in the cannabis industry. Novavax faced FDA holds on its vaccine studies and missed deadlines for approval.

Tilray’s stock has plummeted to about 58 cents, with inconsistent revenue growth and net losses. Despite challenges beyond its control, like regulatory troubles in Canada, Tilray’s poor performance makes it unattractive for investors even at current levels. The CEO predicts federal legalization of cannabis in the U.S., but uncertainties remain.

Novavax, a vaccine maker, encountered FDA holds on its COVID/flu vaccine studies and missed deadlines for vaccine approval. Despite a deal with Sanofi and a new leadership team, Novavax lags in the COVID-19 vaccine market. Regulatory hurdles make Novavax shares unappealing for investors.

The Motley Fool advises against investing in Tilray Brands, highlighting other stocks with potential for high returns. The stock advisor’s past recommendations have yielded significant profits compared to the S&P 500. Tilray Brands faces challenges that make it a risky investment, unlike the top-performing stocks recommended by the advisor.

Read more: 2 Beaten-Down Stocks That Still Aren’t Worth Buying